Fixed Drug Eruption due to Dupilumab

Authors

  • Ayaka Kaneoka Department of Dermatology, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan
  • Natsuko Saito-Sasaki Department of Dermatology, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan
  • Yumiko Sakuragi Department of Dermatology, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan
  • Yu Sawada University of Occupational and Environmental Health

DOI:

https://doi.org/10.2340/actadv.v104.37804

Keywords:

Dupilumab, Fixed drug eruption, Literature review

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Sawada Y, Nakamura M, Tokura Y. Generalized fixed drug eruption caused by pazufloxacin. Acta Derm Venereol 2011; 91: 600-601.

https://doi.org/10.2340/00015555-1132 DOI: https://doi.org/10.2340/00015555-1132

Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9: 316-321.

https://doi.org/10.1097/ACI.0b013e32832cda4c DOI: https://doi.org/10.1097/ACI.0b013e32832cda4c

Bhadresha S, Hughes AJ, McMahon L, Reeken S, Natkunarajah N. Fixed drug eruption secondary to adalimumab. Clin Exp Dermatol 2021; 46: 366-368.

https://doi.org/10.1111/ced.14400 DOI: https://doi.org/10.1111/ced.14400

Cork MJ, Lockshin B, Pinter A, Chen Z, Shumel B, Prescilla R. Clinically meaningful responses to dupilumab among children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who did not achieve clear or almost clear skin according to the investigator's global assessment: a post hoc analysis of a phase 3 trial. Acta Derm Venereol 2024; 104: adv13467.

https://doi.org/10.2340/actadv.v104.13467 DOI: https://doi.org/10.2340/actadv.v104.13467

Dieli F, Sireci G, Scirè E, Salerno A, Bellavia A. Impaired contact hypersensitivity to trinitrochlorobenzene in interleukin-4-deficient mice. Immunology 1999; 98: 71-79.

https://doi.org/10.1046/j.1365-2567.1999.00844.x DOI: https://doi.org/10.1046/j.1365-2567.1999.00844.x

Yung CC, Watts TJ, Haque R. Successful desensitization to metronidazole in a patient with generalized fixed drug eruption. J Allergy Clin Immunol Pract 2020; 8: 769-771.e1.

https://doi.org/10.1016/j.jaip.2019.07.020 DOI: https://doi.org/10.1016/j.jaip.2019.07.020

Downloads

Additional Files

Published

2024-04-20

How to Cite

Kaneoka, A., Saito-Sasaki, N., Sakuragi, Y., & Sawada, Y. (2024). Fixed Drug Eruption due to Dupilumab. Acta Dermato-Venereologica, 104, adv37804. https://doi.org/10.2340/actadv.v104.37804

Issue

Vol. 104 (2024)

Section

Short Communication

Categories

License

Copyright (c) 2024 Ayaka Kaneoka, Natsuko Saito-Sasaki, Yumiko Sakuragi, Yu Sawada

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC